Allygen Biologics

Allygen Biologics is an innovative biotechnology company dedicated to the research and development of targeted conjugate therapeutics. Leveraging multiple proprietary technologies, including Smart TME Activated Release (STAR), the company has established three core technology platforms: bispecific antibody-drug conjugates (bsADCs), antibody-oligonucleotide conjugates (AOCs), and antibody-degrader conjugates (ADOCs). Allygen Biologics maintains a robust pipeline of investigational candidates targeting solid tumors across multiple indications.